Showing results (81-90 of 182) with videos related to
Sort By:
Pageof 19
The Lancet. Oncology|June 2, 2012
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpointsDebora Fumagalli, Philippe L Bedard, Zeina Nahleh, et al.Cancer Research|October 3, 2002
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancerLouise R Howe, Kotha Subbaramaiah, Jay Patel, et al.Breast Cancer Research : BCR|December 19, 2003
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatmentMark E Robson, Pierre O Chappuis, Jaya Satagopan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21Teresa A Gilewski, Govind Ragupathi, Maura Dickler, et al.Cancer|November 21, 2012
Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancerSusan M Domchek, Komal Jhaveri, Sujata Patil, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 5, 2016
Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast CancersGary A Ulaner, Debra A Goldman, Mithat Gönen, et al.The Oncologist|March 19, 2017
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular FunctionFilipa Lynce, Ana Barac, Ming T Tan, et al.Breast Cancer Research and Treatment|April 2, 2017
Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance)Jeanne S Mandelblatt, Ling Cai, George Luta, et al.JAMA|March 3, 2005
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancerHyman B Muss, Susan Woolf, Donald Berry, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840Andrew D Seidman, Donald Berry, Constance Cirrincione, et al.Pageof 19